Clinical trials
Advance Solid Tumors clinical trials
Below are recruiting advance solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,389 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07189949RecruitingPhase 1
Study of HRS-2329 for advanced solid tumors with RAS changes
This trial tests a new drug, HRS-2329, for people with advanced solid tumors that have a RAS mutation or amplification and haven't responded to standard treatments. It aims to see if the drug can help shrink or control the tumors.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06927349RecruitingPhase 1
A trial of BA1301 for advanced solid tumors
This trial tests a new drug, BA1301, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if BA1301 can help shrink or control the cancer.
Harbin, HeilongjiangAges 18–75 - NCT06234397RecruitingPhase 1
Study of BH3120 with or without pembrolizumab for advanced cancers
This trial tests a new drug, BH3120, alone or with pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. It aims to see if the combination can help your immune system fight cancer more effectively.
Tampa, FloridaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06710379RecruitingPhase 1
Testing ADRX-0405 for advanced solid tumors
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
Duarte, CaliforniaAges 18 years+ - NCT06297525RecruitingPhase 1
Testing STP938 for advanced solid tumors
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
St. Petersburg, FloridaAges 18 years+ - NCT07087197RecruitingPhase 1
Study of SKB107 for advanced cancer with bone tumors
This trial tests a new drug, SKB107, for people whose advanced cancer has spread to the bones and standard treatments no longer work. The goal is to see if SKB107 can help shrink or slow these bone tumors.
ShanghaiAges 18–75 - NCT07561437RecruitingEarly Phase 1
NK521 infusion for advanced cancer with fluid buildup
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07046650RecruitingPhase 2
Cisplatin plus gemcitabine for rare tumors after PD-1 therapy
This trial tests a combination of two chemotherapy drugs, cisplatin and gemcitabine, for people with certain rare cancers that no longer respond to a type of immunotherapy called PD-1 inhibitors. The goal is to see how well this treatment works and what side effects it may cause.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05773937RecruitingPhase 1
Study drug for advanced solid tumors after prior treatments
This Phase 1 study tests 9MW2821 in people with advanced solid cancers that have grown despite earlier treatment. It aims to find the safest dose and learn how the drug works, and it may be an option if you can provide tumor tissue and meet key health criteria.
Beijing, Beijing MunicipalityAges 18–80 - NCT07327632RecruitingEarly Phase 1
Testing IBI3026 for advanced solid tumors
This study tests a new drug called IBI3026 for people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if it is safe and helps control the cancer.
Chengdu, SichuanAges 18 years+ - NCT05205109RecruitingPhase 1
Testing a new melanoma drug alone and with pembrolizumab
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
Sydney, New South WalesAges 18 years+ - NCT07321574RecruitingPhase 2
Testing ABP1011T for advanced solid tumors
This trial tests an experimental pill called ABP1011T for people with advanced solid tumors that are no longer responding to standard treatments. It is especially focused on small cell lung cancer and other cancers that might be sensitive to this drug. The goal is to see if the pill can shrink tumors or slow their growth.
Luoyang, HenanAges 18–75 - NCT07181681RecruitingPhase 1
Study of BG-C0902 for advanced solid tumors
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
Houston, TexasAges 18 years+ - NCT07185243Recruiting
Study of virus injection plus immunotherapy for advanced solid tumors
This study tests a new combination treatment: a modified virus (hV01) injected directly into a tumor, plus a drug that helps your immune system attack cancer cells (PD-1 inhibitor). It is for people with advanced solid tumors that have not responded to standard therapies.
Xiamen, FujianAges 18–75 - NCT07032298RecruitingPhase 1
Testing SSGJ-612 for advanced solid tumors with HER2
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
Luoyang, HenanAges 18–75 - NCT05725291RecruitingPhase 1
Early study drug for advanced cancers after other treatments
This Phase 1 trial tests AMT-116, an investigational medicine, in people with advanced solid cancers that can’t be removed by surgery and have gotten worse after standard treatment. It looks for the best safe dose and early signs the treatment may shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT07387068RecruitingPhase 1
Testing GEN1079 for advanced solid tumors
This trial tests an experimental drug called GEN1079 for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if it's safe and if it helps shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07130383RecruitingPhase 2
Study of two experimental drugs for advanced breast cancer and other solid tumors
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05681650RecruitingPhase 1/Phase 2
HER2-targeted CAR-T for HER2-positive advanced solid tumors
This trial tests a new immune-cell therapy (CAR-T) that targets a protein called HER2 in people with advanced or metastatic solid cancers. It may help shrink tumors and control the disease after standard treatments have failed or when there is no clear standard option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07477743RecruitingPhase 1
Study of a new drug combo for advanced solid tumors
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
BeijingAges 18–75 - NCT07469774RecruitingPhase 1/Phase 2
BC3195 plus Keytruda for advanced solid tumors
This trial is testing a new drug called BC3195 combined with pembrolizumab (Keytruda) for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07067567RecruitingPhase 1
Study of AK146D1 injection for advanced solid tumors
This trial tests a new drug called AK146D1 for people with advanced solid tumors that have not responded to standard treatments or no longer work. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT05978102RecruitingPhase 1/Phase 2
Study of STI-7349 for advanced solid cancers
This early-phase study tests STI-7349 (a new cancer treatment) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see how well it can control cancer.
Yiwu, ZhejiangAges 18–80
Hear when a new Advance Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advance solid tumors?
- Yes. Clin2 currently lists 1,389 recruiting advance solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advance solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advance solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.